Trials / Unknown
UnknownNCT05004961
The Performance of Multi-tracer Multimodality PET in Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Investigating the performance of Multi-tracer Multimodality PET in lymphoma
Detailed description
In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.
Conditions
Timeline
- Start date
- 2019-09-15
- Primary completion
- 2023-08-15
- Completion
- 2023-12-31
- First posted
- 2021-08-13
- Last updated
- 2023-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05004961. Inclusion in this directory is not an endorsement.